Chronic inflammation and cytokines in the tumor microenvironment

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Landskron, Glauben ^a   De La Fuente, Marjorie ^a   Thuwajit, Peti ^b   Thuwajit, Chanitra ^b   Hermoso, Marcela A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; AZOXYMETHANE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; DEXTRAN SULFATE; DNA; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 8; METHYLNITROSOUREA; PEPTIDE APTAMER; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 10; SILTUXIMAB; STAT3 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BILE DUCT CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CELL ADHESION; CHRONIC INFLAMMATION; COLITIS; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; FASCIOLA HEPATICA; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; MEDIATOR; METASTASIS; MULTIPLE MYELOMA; MUTAGENIC ACTIVITY; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PHAGOCYTE; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; BILE DUCT TUMOR; CHRONIC DISEASE; COLORECTAL NEOPLASMS; COMPLICATION; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOGENESIS; CHOLANGIOCARCINOMA; CHRONIC DISEASE; COLITIS; COLORECTAL NEOPLASMS; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; OXIDATIVE STRESS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901767734     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/149185     Document Type: Review

References (245)

1. Virchow R., Die Krankhaften Geschwülste 1863 Berlin, Germany
2. Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow? The Lancet 2001 357 9255 539 545 2-s2.0-0035901090 10.1016/S0140-6736(00)04046-0 (Pubitemid 32173595)
3. Hussain S. P., Harris C. C., Inflammation and cancer: an ancient link with novel potentials. International Journal of Cancer 2007 121 11 2373 2380 2-s2.0-35648983903 10.1002/ijc.23173 (Pubitemid 350022405)
4. Yan L., Anderson G. M., DeWitte M., Nakada M. T., Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. European Journal of Cancer 2006 42 6 793 802 2-s2.0-33646078924 10.1016/j.ejca.2006.01.013
5. Medzhitov R., Origin and physiological roles of inflammation. Nature 2008 454 7203 428 435 2-s2.0-47949099098 10.1038/nature07201
6. Norling L. V., Serhan C. N., Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. Journal of Internal Medicine 2010 268 1 15 24 2-s2.0-77953485288 10.1111/j.1365-2796.2010.02235.x
7. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
8. Jess T., Loftus E. V. Jr., Velayos F. S., Harmsen W. S., Zinsmeister A. R., Smyrk T. C., Schleck C. D., Tremaine W. J., Melton L. J. III, Munkholm P., Sandborn W. J., Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006 130 4 1039 1046 2-s2.0-33645998460 10.1053/j.gastro.2005.12.037
9. Zabron A., Edwards R. J., Khan S., The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Disease Models & Mechanisms 2013 6 2 281 292
10. Yoshida T., Kato J., Inoue I., Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. International Journal of Cancer 2014 134 6 1445 1457
11. Vainio H., Boffetta P., Mechanisms of the combined effect of asbestos and smoking in the etiology of lung cancer. Scandinavian Journal of Work, Environment and Health 1994 20 4 235 242 2-s2.0-0027929994 (Pubitemid 24291305)
12. Krieger J. N., Riley D. E., Vesella R. L., Miner D. C., Ross S. O., Lange P. H., Bacterial DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. Journal of Urology 2000 164 4 1221 1228 2-s2.0-0033822738
13. El-Serag H. B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012 142 6 1264 1273 2-s2.0-84860287080 10.1053/j.gastro.2011.12.061
14. Singh R. K., Gutman M., Reich R., Bar-Eli M., Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Research 1995 55 16 3669 3674 2-s2.0-0029102881
15. Bats A. S., Zafrani Y., Pautier P., Duvillard P., Morice P., Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature. Fertility and Sterility 2008 90 4 1197.e13 1197.e16 2-s2.0-52949118155 10.1016/j.fertnstert.2007.08.080
16. Fox J. G., Dewhirst F. E., Shen Z., Feng Y., Taylor N. S., Paster B. J., Ericson R. L., Lau C. N., Correa P., Araya J. C., Roa I., Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 1998 114 4 I 755 763 2-s2.0-0031899969 10.1016/S0016-5085(98)70589-X (Pubitemid 28160410)
17. Levin B., Gallbladder carcinoma. Annals of Oncology 1999 10 4 S129 S130 2-s2.0-0032809216 (Pubitemid 29333414)
18. Cameron A. J., Carpenter H. A., Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. American Journal of Gastroenterology 1997 92 4 586 591 2-s2.0-0030933230 (Pubitemid 27184369)
19. Murata M., Thanan R., Ma N., Kawanishi S., Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. Journal of Biomedicine and Biotechnology 2012 2012 11 2-s2.0-84858116393 10.1155/2012/623019 623019
20. Luo J.-L., Maeda S., Hsu L.-C., Yagita H., Karin M., Inhibition of NF- B in cancer cells converts inflammation- induced tumor growth mediated by TNF α to TRAIL-mediated tumor regression. Cancer Cell 2004 6 3 297 305 2-s2.0-4544224979 10.1016/j.ccr.2004.08.012 (Pubitemid 39222042)
21. Bates R. C., Mercurio A. M., Tumor necrosis factor- α stimulates the epithelial-tomesenchymal transition of human colonic organoids. Molecular Biology of the Cell 2003 14 5 1790 1800 2-s2.0-0037572319 10.1091/mbc.E02-09- 0583 (Pubitemid 36583533)
22. Danese S., Sans M., de la Motte C., Graziani C., West G., Phillips M. H., Pola R., Rutella S., Willis J., Gasbarrini A., Fiocchi C., Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006 130 7 2060 2073 2-s2.0-33744510694 10.1053/j.gastro.2006.03.054 (Pubitemid 43816964)
23. Al-Bahrani R., Abuetabh Y., Zeitouni N., Sergi C., Cholangiocarcinoma: risk factors, environmental influences and oncogenesis. Annals of Clinical & Laboratory Science 2013 43 2 195 210
24. Hanada S., Harada M., Koga H., Kawaguchi T., Taniguchi E., Kumashiro R., Ueno T., Ueno Y., Ishii M., Sakisaka S., Sata M., Tumor necrosis factor- α and interferon- γ directly impair epithelial barrier function in cultured moused cholangiocytes. Liver International 2003 23 1 3 11 2-s2.0-0037532351 (Pubitemid 37265768)
25. Komori J., Marusawa H., Machimoto T., Endo Y., Kinoshita K., Kou T., Haga H., Ikai I., Uemoto S., Chiba T., Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008 47 3 888 896 2-s2.0-40949132893 10.1002/hep.22125 (Pubitemid 351449680)
26. Techasen A., Namwat N., Loilome W., Tumor necrosis factor- α (TNF- α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma. Medical Oncology 2012 29 5 3083 3091
27. Camoglio L., Te Velde A. A., Tigges A. J., Das P. K., Van Deventer S. J. H., Altered expression of interferon- γ and interleukin-4 in inflammatory bowel disease. Inflammatory Bowel Diseases 1998 4 4 285 290 2-s2.0-0032199208 (Pubitemid 128699868)
28. Ito R., Shin-Ya M., Kishida T., Urano A., Takada R., Sakagami J., Imanishi J., Kita M., Ueda Y., Iwakura Y., Kataoka K., Okanoue T., Mazda O., Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clinical and Experimental Immunology 2006 146 2 330 338 2-s2.0-33750049009 10.1111/j.1365-2249.2006.03214.x (Pubitemid 44581349)
29. Bruewer M., Luegering A., Kucharzik T., Parkos C. A., Madara J. L., Hopkins A. M., Nusrat A., Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. Journal of Immunology 2003 171 11 6164 6172 2-s2.0-0345447585 (Pubitemid 37467239)
30. Osawa E., Nakajima A., Fujisawa T., Kawamura Y. I., Toyama-Sorimachi N., Nakagama H., Dohi T., Predominant T helper type 2-inflammatory responses promote murine colon cancers. International Journal of Cancer 2006 118 9 2232 2236 2-s2.0-33645659501 10.1002/ijc.21639
31. Hisamatsu T., Watanabe M., Ogata H., Ezaki T., Hozawa S., Ishii H., Kanai T., Hibi T., Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Research 1999 59 23 5927 5931 2-s2.0-0033460195 (Pubitemid 30004953)
32. Paulukat J., Bosmann M., Nold M., Garkisch S., Kämpfer H., Frank S., Raedle J., Zeuzem S., Pfeilschifter J., Mühl H., Expression and release of IL-18 binding protein in response to IFN- γ Journal of Immunology 2001 167 12 7038 7043 2-s2.0-0035892991 (Pubitemid 33144199)
33. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., Scheller J., Rose-John S., Kado S.-I., Takada T., Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. Journal of Immunology 2010 184 3 1543 1551 2-s2.0-77949326158 10.4049/jimmunol.0801217
34. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.-Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009 15 2 103 113 2-s2.0-58649108302 10.1016/j.ccr.2009.01.001
35. Middleton K., Jones J., Lwin Z., Coward J. I. G., Interleukin-6: an angiogenic target in solid tumours. Critical Reviews in Oncology/Hematology 2014 89 1 129 139
36. Elsharkawy A. M., Mann D. A., Nuclear factor- B and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007 46 2 590 597 2-s2.0-34548321204 10.1002/hep.21802 (Pubitemid 47344795)
37. Meng F., Wehbe-Janek H., Henson R., Smith H., Patel T., Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008 27 3 378 386 2-s2.0-38049152791 10.1038/sj.onc.1210648
38. Bates R. C., Mercurio A. M., The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biology and Therapy 2005 4 4 365 370 2-s2.0-25144451812 (Pubitemid 41351251)
39. Feagins L. A., Role of transforming growth factor- β in inflammatory bowel disease and colitis-associated colon cancer. Inflammatory Bowel Diseases 2010 16 11 1963 1968 2-s2.0-78249231410 10.1002/ibd.21281
40. Sato Y., Harada K., Itatsu K., Ikeda H., Kakuda Y., Shimomura S., Ren X. S., Yoneda N., Sasaki M., Nakanuma Y., Epithelial-mesenchymal transition induced by transforming growth factor- β 1/snail activation aggravates invasive growth of cholangiocarcinoma. American Journal of Pathology 2010 177 1 141 152 2-s2.0-77954586069 10.2353/ajpath.2010.090747
41. Ning Y., Manegold P. C., Hong Y. K., Zhang W., Pohl A., Lurje G., Winder T., Yang D., LaBonte M. J., Wilson P. M., Ladner R. D., Lenz H.-J., Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. International Journal of Cancer 2011 128 9 2038 2049 2-s2.0-79952471898 10.1002/ijc.25562
42. Spirlì C., Fabris L., Duner E., Fiorotto R., Ballardini G., Roskams T., Larusso N. F., Sonzogni A., Okolicsanyi L., Strazzabosco M., Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003 124 3 737 753 2-s2.0-0037370065 10.1053/gast.2003.50100 (Pubitemid 36268491)
43. Spiral C., Nathanson M. H., Fiorotto R., Duner E., Denson L. A., Sanz J. M., Di Virgilio F., Okolicsanyi L., Casagrande F., Strazzabosco M., Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001 121 1 156 169 2-s2.0-0034959516 (Pubitemid 32591526)
44. Sturlan S., Oberhuber G., Beinhauer B. G., Tichy B., Kappel S., Wang J., Rogy M. A., Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 2001 22 4 665 671 2-s2.0-0035073083 (Pubitemid 32288669)
45. Hasita H., Komohara Y., Okabe H., Masuda T., Ohnishi K., Lei X. F., Beppu T., Baba H., Takeya M., Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Science 2010 101 8 1913 1919 2-s2.0-77954855351 10.1111/j.1349-7006.2010.01614.x
46. Liu J., Duan Y., Cheng X., Chen X., Xie W., Long H., Lin Z., Zhu B., IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochemical and Biophysical Research Communications 2011 407 2 348 354 2-s2.0-79953681584 10.1016/j.bbrc.2011.03.021
47. Gounaris E., Blatner N. R., Dennis K., Magnusson F., Gurish M. F., Strom T. B., Beckhove P., Gounari F., Khazaie K., T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Research 2009 69 13 5490 5497 2-s2.0-67650462939 10.1158/0008-5472.CAN-09-0304
48. Gu F.-M., Gao Q., Shi G.-M., Intratumoral IL-17+ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Annals of Surgical Oncology 2012 19 8 2506 2514
49. Stolfi C., Rizzo A., Franzè E., Rotondi A., Fantini M. C., Sarra M., Caruso R., Monteleone I., Sileri P., Franceschilli L., Caprioli F., Ferrero S., MacDonald T. T., Pallone F., Monteleone G., Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. Journal of Experimental Medicine 2011 208 11 2279 2290 2-s2.0-80055105733 10.1084/jem.20111106
50. Zamarron B. F., Chen W., Dual roles of immune cells and their factors in cancer development and progression. International Journal of Biological Sciences 2011 7 5 651 658 2-s2.0-79960122931
51. Popa C., Netea M. G., Van Riel P. L. C. M., Van Der Meer J. W. M., Stalenhoef A. F. H., The role of TNF- α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research 2007 48 4 751 762 2-s2.0-34147126829 10.1194/jlr.R600021-JLR200 (Pubitemid 46557880)
52. Moore R. J., Owens D. M., Stamp G., Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nature Medicine 1999 5 7 828 831 (Pubitemid 29318619)
53. Szlosarek P., Charles K. A., Balkwill F. R., Tumour necrosis factor- α as a tumour promoter. European Journal of Cancer 2006 42 6 745 750 2-s2.0-33646472252 10.1016/j.ejca.2006.01.012
54. Chen G., Goeddel D. V., TNF-R1 signaling: a beautiful pathway. Science 2002 296 5573 1634 1635 2-s2.0-0037204948 10.1126/science.1071924 (Pubitemid 34579145)
55. Havell E. A., Fiers W., North R. J., The antitumor function of tumor necrosis factor (TNF)-I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. Journal of Experimental Medicine 1988 167 3 1067 1085 2-s2.0-0023940875
56. Wiemann B., Starnes C. O., Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology and Therapeutics 1994 64 3 529 564 2-s2.0-0028081705 10.1016/0163-7258(94)90023-X (Pubitemid 24381235)
57. Lejeune F. J., Rüegg C., Liénard D., Clinical applications of TNF-alpha in cancer. Current Opinion in Immunology 1998 10 5 573 580
58. Herman J. M., Wild A. T., Wang H., Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Journal of Clinical Oncology 2013 31 7 886 894
59. Chang K. J., Reid T., Senzer N., Swisher S., Pinto H., Hanna N., Chak A., Soetikno R., Phase I evaluation of TNFerade Biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointestinal Endoscopy 2012 75 1139 1146 2-s2.0-84859747134 10.1016/j.gie.2012.01.042
60. Anderson G. M., Nakada M. T., DeWitte M., Tumor necrosis factor- α in the pathogenesis and treatment of cancer. Current Opinion in Pharmacology 2004 4 4 314 320 2-s2.0-3342968806 10.1016/j.coph.2004.04.004 (Pubitemid 38987055)
61. Balkwill F., TNF- α in promotion and progression of cancer. Cancer and Metastasis Reviews 2006 25 3 409 416 2-s2.0-33845524008 10.1007/s10555-006- 9005-3 (Pubitemid 44922358)
62. Woo C.-H., Eom Y.-W., Yoo M.-H., You H.-J., Han H. J., Song W. K., Yoo Y. J., Chun J.-S., Kim J.-H., Tumor necrosis factor- α generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. Journal of Biological Chemistry 2000 275 41 32357 32362 2-s2.0-0034644753
63. Hussain S. P., Hofseth L. J., Harris C. C., Radical causes of cancer. Nature Reviews Cancer 2003 3 4 276 285 2-s2.0-0038352053 (Pubitemid 37328863)
64. Noach L. A., Bosma N. B., Jansen J., Hoek F. J., Van Deventer S. J. H., Tytgat G. N. J., Mucosal tumor necrosis factor- α interleukin-1 β and interleukin-8 production in patients with helicobacter pylori infection. Scandinavian Journal of Gastroenterology 1994 29 5 425 429 2-s2.0-0028326795 (Pubitemid 24144511)
65. Suganuma M., Watanabe T., Yamaguchi K., Takahashi A., Fujiki H., Human gastric cancer development with TNF- α -inducing protein secreted from Helicobacter pylori. Cancer Letters 2012 322 2 133 138 2-s2.0-84859716678 10.1016/j.canlet.2012.03.027
66. Kwong J., Franky L. C., Wong K.-K., Birrer M. J., Archibald K. M., Balkwill F. R., Berkowitz R. S., Mok S. C., Inflammatory cytokine tumor necrosis factor α confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009 11 6 529 541 2-s2.0-66449125885 10.1593/neo.09112
67. Ohri C. M., Shikotra A., Green R. H., Waller D. A., Bradding P., Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010 10, article 323 2-s2.0-77953709449 10.1186/1471-2407-10-323
68. Lee S. H., Hong H. S., Liu Z. X., TNF α enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochemical and Biophysical Research Communications 2012 424 1 58 64
69. Heikkilä K., Ebrahim S., Lawlor D. A., Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. European Journal of Cancer 2008 44 7 937 945 2-s2.0-42649129014 10.1016/j.ejca.2008.02. 047
70. Hodge D. R., Hurt E. M., Farrar W. L., The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer 2005 41 16 2502 2512 2-s2.0-27544476971 10.1016/j.ejca.2005.08.016 (Pubitemid 41540626)
71. Gasche J. A., Hoffmann J., Boland C. R., Goel A., Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. International Journal of Cancer 2011 129 5 1053 1063 2-s2.0-79959743101 10.1002/ijc.25764
72. Kinoshita H., Hirata Y., Nakagawa H., Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS ONE 2013 8 4 e60914
73. Chatterjee M., Stühmer T., Herrmann P., Bommert K., Dörken B., Bargou R. C., Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004 104 12 3712 3721 2-s2.0-9444273447 10.1182/blood-2004-04-1670 (Pubitemid 39564449)
74. Hilbert D. M., Kopf M., Mock B. A., Köhler G., Rudikoff S., Interleukin 6 is essential for in vivo development of B lineage neoplasms. Journal of Experimental Medicine 1995 182 1 243 248 2-s2.0-0029069307 10.1084/jem.182.1.243
75. Kim S.-Y., Kang J. W., Song X., Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signaling 2013 25 4 961 969
76. Song L., Rawal B., Nemeth J. A., Haura E. B., JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Molecular Cancer Therapeutics 2011 10 3 481 494 2-s2.0-79955780881 10.1158/1535-7163.MCT-10-0502
77. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D. A., Thompson R., Schioppa T., Nemeth J., Vermeulen J., Singh N., Avril N., Cummings J., Rexhepaj E., Jirström K., Gallagher W. M., Brennan D. J., McNeish I. A., Balkwill F. R., Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research 2011 17 18 6083 6096 2-s2.0-80052855899 10.1158/1078-0432.CCR-11-0945
78. Kurzrock R., Voorhees P. M., Casper C., A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical Cancer Research 2013 19 13 3659 3670
79. Rossi J.-F., Négrier S., James N. D., Kocak I., Hawkins R., Davis H., Prabhakar U., Qin X., Mulders P., Berns B., A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer 2010 103 8 1154 1162 2-s2.0-77957995258 10.1038/sj.bjc.6605872
80. Dorff T. B., Goldman B., Pinski J. K., Mack P. C., Lara P. N. Jr., Van Veldhuizen P. J. Jr., Quinn D. I., Vogelzang N. J., Thompson I. M. Jr., Hussain M. H. A., Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clinical Cancer Research 2010 16 11 3028 3034 2-s2.0-77953091816 10.1158/1078-0432.CCR-09-3122
81. Santibañez J. F., Quintanilla M., Bernabeu C., TGF- β /TGF- β receptor system and its role in physiological and pathological conditions. Clinical Science 2011 121 6 233 251
82. Massagué J., TGFbeta in cancer. Cell 2008 134 2 215 230
83. Matsuzaki K., Smad phospho-isoforms direct context-dependent TGF- β signaling. Cytokine & Growth Factor Reviews 2013 24 4 385 399
84. Morrison C. D., Parvani J. G., Schiemann W. P., The relevance of the TGF- β Paradox to EMT-MET programs. Cancer Letters 2013 341 1 30 40
85. Malliri A., Andrew Yeudall W., Nikolic M., Crouch D. H., Kenneth Parkinson E., Ozanne B., Sensitivity to transforming growth factor β 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21(waf1) induction are important early events. Cell Growth and Differentiation 1996 7 10 1291 1304 2-s2.0-10244232854 (Pubitemid 26360678)
86. Guasch G., Schober M., Pasolli H. A., Conn E. B., Polak L., Fuchs E., Loss of TGF& signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 2007 12 4 313 327 2-s2.0-35148832173 10.1016/j.ccr.2007.08.020 (Pubitemid 47539305)
87. Bierie B., Moses H. L., TGF- β and cancer. Cytokine and Growth Factor Reviews 2006 17 1-2 29 40 2-s2.0-30944432734 10.1016/j.cytogfr.2005.09. 006 (Pubitemid 43117514)
88. Levy L., Hill C. S., Alterations in components of the TGF- β superfamily signaling pathways in human cancer. Cytokine and Growth Factor Reviews 2006 17 1-2 41 58 2-s2.0-30944444113 10.1016/j.cytogfr.2005.09.009 (Pubitemid 43117515)
89. Connolly E. C., Freimuth J., Akhurst R. J., Complexities of TGF- β targeted cancer therapy. International Journal of Biological Sciences 2012 8 7 964 978
90. Sabat R., Grütz G., Warszawska K., Kirsch S., Witte E., Wolk K., Geginat J., Biology of interleukin-10. Cytokine and Growth Factor Reviews 2010 21 5 331 344 2-s2.0-78649720282 10.1016/j.cytogfr.2010.09.002
91. Costa N. L., Valadares M. C., Souza P. P. C., Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncology 2013 49 3 216 223
92. Gastl G. A., Abrams J. S., Nanus D. M., Oosterkamp R., Silver J., Liu F., Chen M., Albino A. P., Bander N. H., Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. International Journal of Cancer 1993 55 1 96 101 2-s2.0-0027317738 (Pubitemid 23261713)
93. Finbloom D. S., Winestock K. D., IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 α and STAT3 complexes in human T cells and monocytes. Journal of Immunology 1995 155 3 1079 1090 2-s2.0-0029118395
94. Schottelius A. J. G., Mayo M. W., Balfour Sartor R., Baldwin A. S. Jr., Interleukin-10 signaling blocks inhibitor of B kinase activity and nuclear factor B DNA binding. Journal of Biological Chemistry 1999 274 45 31868 31874 2-s2.0-0033527549 10.1074/jbc.274.45.31868 (Pubitemid 29522916)
95. Berg D. J., Davidson N., Kühn R., Müller W., Menon S., Holland G., Thompson-Snipes L., Leach M. W., Rennick D., Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ Th1-like responses. Journal of Clinical Investigation 1996 98 4 1010 1020 2-s2.0-0029813545 (Pubitemid 26293320)
96. + regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. American Journal of Pathology 2003 162 2 691 702 2-s2.0-0037331279 (Pubitemid 36267876)
97. + regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Research 2003 63 18 6042 6050 2-s2.0-0141731259 (Pubitemid 37187508)
98. Lin W.-W., Karin M., A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation 2007 117 5 1175 1183 2-s2.0-34248141100 10.1172/JCI31537 (Pubitemid 46718402)
99. Kundu N., Fulton A. M., Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cellular Immunology 1997 180 1 55 61 2-s2.0-0031586331 10.1006/cimm.1997.1176 (Pubitemid 27433618)
100. Hamidullah H., Changkija B., Konwar R., Role of interleukin-10 in breast cancer. Breast Cancer Research and Treatment 2012 133 1 11 21 2-s2.0-84860341228 10.1007/s10549-011-1855-x
101. Braun D. A., Fribourg M., Sealfon S. C., Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. Journal of Biological Chemistry 2013 288 5 2986 2993
102. Sredni B., Weil M., Khomenok G., Lebenthal I., Teitz S., Mardor Y., Ram Z., Orenstein A., Kershenovich A., Michowiz S., Cohen Y. I., Rappaport Z. H., Freidkin I., Albeck M., Longo D. L., Kalechman Y., Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Research 2004 64 5 1843 1852 2-s2.0-12144289718 10.1158/0008-5472.CAN-03-3179 (Pubitemid 38428710)
103. Alas S., Emmanouilides C., Bonavida B., Inhibition of interleukin 10 by Rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clinical Cancer Research 2001 7 3 709 723 2-s2.0-0034894958 (Pubitemid 32707998)
104. Zeng L., O'Connor C., Zhang J., Kaplan A. M., Cohen D. A., IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010 49 3 294 302 2-s2.0-75449085685 10.1016/j.cyto.2009.11.015
105. Lech-Maranda E., Bienvenu J., Michallet A.-S., Houot R., Robak T., Coiffier B., Salles G., Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. European Cytokine Network 2006 17 1 60 66 2-s2.0-33746083294
106. Ogden C. A., Pound J. D., Batth B. K., Owens S., Johannessen I., Wood K., Gregory C. D., Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. Journal of Immunology 2005 174 5 3015 3023 2-s2.0-14044259331 (Pubitemid 40279722)
107. Bedard K., Krause K.-H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews 2007 87 1 245 313 2-s2.0-33846794822 10.1152/physrev.00044.2005 (Pubitemid 46209993)
108. Förstermann U., Sessa W. C., Nitric oxide synthases: regulation and function. European Heart Journal 2012 33 7 829 837 2-s2.0-84859487532 10.1093/eurheartj/ehr304
109. Flannagan R. S., Cosío G., Grinstein S., Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nature Reviews Microbiology 2009 7 5 355 366 2-s2.0-64749091309 10.1038/nrmicro2128
110. Finkel T., Reactive oxygen species and signal transduction. IUBMB Life 2001 52 1-2 3 6 2-s2.0-0036139524 10.1080/15216540252774694 (Pubitemid 33769662)
111. Yang D., Elner S. G., Bian Z.-M., Till G. O., Petty H. R., Elner V. M., Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Experimental Eye Research 2007 85 4 462 472 2-s2.0-34948822892 10.1016/j.exer.2007.06.013 (Pubitemid 47531733)
112. Sturrock A., Cahill B., Norman K., Huecksteadt T. P., Hill K., Sanders K., Karwande S. V., Stringham J. C., Bull D. A., Gleich M., Kennedy T. P., Hoidal J. R., Transforming growth factor- β 1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 2006 290 4 L661 L673 2-s2.0-33646593852 10.1152/ajplung.00269.2005 (Pubitemid 43725071)
113. da Silva Krause M., Bittencourt A., Homem de Bittencourt P. I., Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release, and redox status in a clonal pancreatic β -cell line and mouse islets. Journal of Endocrinology 2012 214 3 301 311
114. Rieder G., Hofmann J. A., Hatz R. A., Stolte M., Enders G. A., Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. International Journal of Medical Microbiology 2003 293 6 403 412 2-s2.0-0347753322 10.1078/1438-4221-00280 (Pubitemid 38082346)
115. Rachmilewitz D., Stamler J. S., Bachwich D., Karmeli F., Ackerman Z., Podolsky D. K., Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995 36 5 718 723 2-s2.0-0028998288
116. Hofseth L. J., Saito S., Perwez Hussain S., Espey M. G., Miranda K. M., Araki Y., Jhappan C., Higashimoto Y., He P., Linke S. P., Quezado M. M., Zurer I., Rotter V., Wink D. A., Appella E., Harris C. C., Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America 2003 100 1 143 148 2-s2.0-0037422535 10.1073/pnas.0237083100 (Pubitemid 36078042)
117. Ma N., Adachi Y., Hiraku Y., Horiki N., Horiike S., Imoto I., Pinlaor S., Murata M., Semba R., Kawanishi S., Accumulation of 8-nitroguanine in human gastric epithelium induced by Helicobacter pylori infection. Biochemical and Biophysical Research Communications 2004 319 2 506 510 2-s2.0-2642512213 10.1016/j.bbrc.2004.04.193 (Pubitemid 38725975)
118. Horiike S., Kawanishi S., Kaito M., Ma N., Tanaka H., Fujita N., Iwasa M., Kobayashi Y., Hiraku Y., Oikawa S., Murata M., Wang J., Semba R., Watanabe S., Adachi Y., Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. Journal of Hepatology 2005 43 3 403 410 2-s2.0-23444437459 10.1016/j.jhep.2005.03.026 (Pubitemid 41111420)
119. Jaiswal M., LaRusso N. F., Shapiro R. A., Billiar T. R., Gores G. J., Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001 120 1 190 199 2-s2.0-0035170217 (Pubitemid 32061883)
120. Tang C.-H., Wei W., Liu L., Regulation of DNA repair by S-nitrosylation. Biochimica et Biophysica Acta 2012 1820 6 730 735 2-s2.0-84860441601 10.1016/j.bbagen.2011.04.014
121. Li Q., Fu G.-B., Zheng J.-T., NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. Biochimica et Biophysica Acta 2013 1833 12 3375 3385
122. Jung S.-N., Yang W. K., Kim J., Kim H. S., Kim E. J., Yun H., Park H., Kim S. S., Choe W., Kang I., Ha J., Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 2008 29 4 713 721 2-s2.0-41849094797 10.1093/carcin/bgn032 (Pubitemid 351494158)
123. Rao C. V., Indranie C., Simi B., Manning P. T., Connor J. R., Reddy B. S., Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Research 2002 62 1 165 170 2-s2.0-0036144387 (Pubitemid 34074001)
124. Takahashi M., Kitahashi T., Ishigamori R., Mutoh M., Komiya M., Sato H., Kamanaka Y., Naka M., Maruyama T., Sugimura T., Wakabayashi K., Increased expression of inducible nitric oxide synthase (iNOS) in N-nitrosobis(2- oxopropyl)amine-induced hamster pancreatic carcinogenesis and prevention of cancer development by ONO-1714, an iNOS inhibitor. Carcinogenesis 2008 29 8 1608 1613 2-s2.0-49649100910 10.1093/carcin/bgn152
125. Li B., Alli R., Vogel P., Geiger T. L., IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunology 2013
126. Zhu G., Du Q., Wang X., TNF- α promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. International Journal of Molecular Medicine 2014
127. Charles K. A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., Chakravarty P., Thompson R. G., Kollias G., Smyth J. F., Balkwill F. R., Hagemann T., The tumor-promoting actions of TNF- α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation 2009 119 10 3011 3023 2-s2.0-70349668946 10.1172/JCI39065
128. He D., Li H., Yusuf N., Elmets C. A., Athar M., Katiyar S. K., Xu H., IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE 2012 7 2 2-s2.0-84857125493 10.1371/journal.pone.0032126 e32126
129. Shouda T., Hiraoka K., Komiya S., Hamada T., Zenmyo M., Iwasaki H., Isayama T., Fukushima N., Nagata K., Yoshimura A., Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Letters 2006 231 2 176 184 2-s2.0-29844433086 10.1016/j.canlet.2005.01.042 (Pubitemid 43038728)
130. Tang Q., Li J., Zhu H., Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators of Inflammation 2013 2013 13 10.1155/2013/713859 713859
131. Zheng T., Hong X., Wang J., Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014 59 3 935 946
132. Dai Y., Jiao H., Teng G., Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. Molecular Cancer Therapeutics 2014
133. García-Hernández M. L., Hernández-Pando R., Gariglio P., Berumen J., Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002 105 2 231 243 2-s2.0-0036173389 10.1046/j.1365-2567.2002.01363.x (Pubitemid 34146690)
134. Baum B., Settleman J., Quinlan M. P., Transitions between epithelial and mesenchymal states in development and disease. Seminars in Cell and Developmental Biology 2008 19 3 294 308 2-s2.0-41549162752 10.1016/j.semcdb. 2008.02.001
135. Kalluri R., Weinberg R. A., The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 2009 119 6 1420 1428 2-s2.0-67650999875 10.1172/JCI39104
136. Thiery J. P., Sleeman J. P., Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006 7 2 131 142 2-s2.0-33244463813 10.1038/nrm1835 (Pubitemid 43278296)
137. Xu J., Lamouille S., Derynck R., TGF- Β -induced epithelial to mesenchymal transition. Cell Research 2009 19 2 156 172 2-s2.0-59449090107 10.1038/cr.2009.5
138. Thiery J. P., Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer 2002 2 6 442 454
139. Tirino V., Camerlingo R., Bifulco K., TGF- β 1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death & Disease 2013 4 5, article e620
140. Ellenrieder V., Hendler S. F., Boeck W., Seufferlein T., Menke A., Ruhland C., Adler G., Gress T. M., Transforming growth factor β 1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Research 2001 61 10 4222 4228 2-s2.0-0035872426 (Pubitemid 32720992)
141. Willis B. C., Liebler J. M., Luby-Phelps K., Nicholson A. G., Crandall E. D., Du Bois R. M., Borok Z., Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor- β 1: potential role in idiopathic pulmonary fibrosis. American Journal of Pathology 2005 166 5 1321 1332 2-s2.0-17844384822 (Pubitemid 40586504)
142. Yamagishi T., Ando K., Nakamura H., Nakajima Y., Expression of the Tgf β 2 gene during chick embryogenesis. Anatomical Record 2012 295 2 257 267 2-s2.0-84855773222 10.1002/ar.22400
143. Sato M., Muragaki Y., Saika S., Roberts A. B., Ooshima A., Targeted disruption of TGF- β 1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Journal of Clinical Investigation 2003 112 10 1486 1494 2-s2.0-0346727324 10.1172/JCI200319270 (Pubitemid 38056275)
144. Valcourt U., Kowanetz M., Niimi H., Heldin C.-H., Moustakas A., TGF- β and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Molecular Biology of the Cell 2005 16 4 1987 2002 2-s2.0-16344378397 10.1091/mbc.E04-08-0658 (Pubitemid 40471965)
145. Abulaiti A., Shintani Y., Funaki S., Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF- β signaling by IL-6. Lung Cancer 2013 82 2 204 213
146. Maier H. J., Schmidt-Straßburger U., Huber M. A., Wiedemann E. M., Beug H., Wirth T., NF- B promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Letters 2010 295 2 214 228 2-s2.0-77954030498 10.1016/j.canlet.2010.03.003
147. Kumar M., Allison D. F., Baranova N. N., NF- B regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS ONE 2013 8 7 e68597
148. Yadav A., Kumar B., Datta J., Teknos T. N., Kumar P., IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Molecular Cancer Research 2011 9 12 1658 1667 2-s2.0-84055207487 10.1158/1541-7786.MCR-11-0271
149. Wang Z., Li Y., Sarkar F. H., Signaling mechanism(S) of reactive oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem cells in tumor progression. Current Stem Cell Research and Therapy 2010 5 1 74 80 2-s2.0-77949381018 10.2174/157488810790442813
150. Rhyu D. Y., Yang Y., Ha H., Lee G. T., Song J. S., Uh S.-T., Lee H. B., Role of reactive oxygen species in TGF- β 1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. Journal of the American Society of Nephrology 2005 16 3 667 675 2-s2.0-20544437490 10.1681/ASN.2004050425 (Pubitemid 41725103)
151. Cao Y., Tumor angiogenesis and therapy. Biomedicine and Pharmacotherapy 2005 59 2 S340 S343 2-s2.0-33644532890 10.1016/S0753-3322(05)80070-8
152. +) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes. Molecules and Cells 2013 36 5 432 438
153. Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C., Dual role of tumor necrosis factor- α in angiogenesis. American Journal of Pathology 1992 140 3 539 544 2-s2.0-0026568694
154. Weichselbaum R. R., Kufe D. W., Hellman S., Rasmussen H. S., King C. R., Fischer P. H., Mauceri H. J., Radiation-induced tumour necrosis factor- α expression: clinical application of transcriptional and physical targeting of gene therapy. The Lancet Oncology 2002 3 11 665 671 2-s2.0-0036845222 10.1016/S1470-2045(02)00900-2 (Pubitemid 35314909)
155. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., Kuwano M., Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Molecular and Cellular Biology 1997 17 7 4015 4023 2-s2.0-0031009807 (Pubitemid 27281877)
156. Li B., Vincent A., Cates J., Brantley-Sieders D. M., Polk D. B., Young P. P., Low levels of tumor necrosis factor α increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Research 2009 69 1 338 348 2-s2.0-58249117625 10.1158/0008-5472.CAN-08- 1565
157. Kulbe H., Thompson R., Wilson J. L., Robinson S., Hagemann T., Fatah R., Gould D., Ayhan A., Balkwill F., The inflammatory cytokine tumor necrosis factor- α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Research 2007 67 2 585 592 2-s2.0-33846682591 10.1158/0008-5472.CAN-06-2941 (Pubitemid 46192196)
158. Eldesoky A., Shouma A., Mosaad Y., Elhawary A., Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi Journal of Gastroenterology 2011 17 3 170 173 2-s2.0-80052536647
159. Kim H. K., Song K. S., Park Y. S., Kang Y. H., Lee Y. J., Lee K. R., Kim H. K., Ryu K. W., Bae J. M., Kim S., Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer 2003 39 2 184 191 2-s2.0-0037220119 10.1016/S0959-8049(02)00596-8 (Pubitemid 36057068)
160. Huang S.-P., Wu M.-S., Shun C.-T., Wang H.-P., Lin M.-T., Kuo M.-L., Lin J.-T., Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. Journal of Biomedical Science 2004 11 4 517 527 2-s2.0-2642579084 10.1159/000077902 (Pubitemid 38721036)
161. Wei L.-H., Kuo M.-L., Chen C.-A., Chou C.-H., Lai K.-B., Lee C.-N., Hsieh C.-Y., Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003 22 10 1517 1527 2-s2.0-0037435011 10.1038/sj.onc.1206226 (Pubitemid 36390601)
162. Feurino L. W., Zhang Y., Bharadwaj U., Zhang R., Li F., Fisher W. E., Brunicardi F. C., Chen C., Yao Q., Li M., IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biology and Therapy 2007 6 7 1096 1100 2-s2.0-41349099759 (Pubitemid 351574962)
163. Boreddy S. R., Sahu R. P., Srivastava S. K., Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF- α /VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS ONE 2011 6 10 2-s2.0-80053925842 10.1371/journal.pone.0025799 e25799
164. Wikström P., Stattin P., Franck-Lissbrant I., Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998 37 1 19 29 (Pubitemid 28385181)
165. Saito H., Tsujitani S., Oka S., The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999 86 8 1455 1462 (Pubitemid 29489778)
166. Dickson M. C., Martin J. S., Cousins F. M., Kulkarni A. B., Karlsson S., Akhurst R. J., Defective haematopoiesis and vasculogenesis in transforming growth factor- β 1 knock out mice. Development 1995 121 6 1845 1854 2-s2.0-0029074681
167. Huang S., Xie K., Bucana C. D., Ullrich S. E., Bar-Eli M., Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clinical Cancer Research 1996 2 12 1969 1979 2-s2.0-0030443062 (Pubitemid 27006629)
168. Stearns M. E., Rhim J., Wang M., Interleukin 10 (IL-10) inhibition of primary human prostate cell- induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clinical Cancer Research 1999 5 1 189 196 2-s2.0-0032953206 (Pubitemid 29045193)
169. Kohno T., Mizukami H., Suzuki M., Saga Y., Takei Y., Shimpo M., Matsushita T., Okada T., Hanazono Y., Kume A., Sato I., Ozawa K., Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Research 2003 63 16 5091 5094 2-s2.0-0042014500 (Pubitemid 37022649)
170. Orosz P., Echtenacher B., Falk W., Ruschoff J., Weber D., Mannel D. N., Enhancement of experimental metastasis by tumor necrosis factor. Journal of Experimental Medicine 1993 177 5 1391 1398 2-s2.0-0027534917 (Pubitemid 23117129)
171. Orosz P., Kruger A., Hubbe M., Ruschoff J., Von Hoegen P., Mannel D. N., Promotion of experimental liver metastasis by tumor necrosis factor. International Journal of Cancer 1995 60 6 867 871 2-s2.0-0028918917 10.1002/ijc.2910600624
172. Kim S., Takahashi H., Lin W.-W., Descargues P., Grivennikov S., Kim Y., Luo J.-L., Karin M., Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009 457 7225 102 106 2-s2.0-58149269348 10.1038/nature07623
173. Egberts J.-H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., Von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A., Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Research 2008 68 5 1443 1450 2-s2.0-40449090323 10.1158/0008-5472.CAN-07-5704 (Pubitemid 351346852)
174. Roodman G. D., Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003 97 3 733 738 2-s2.0-0037304016 (Pubitemid 36125808)
175. Tawara K., Oxford J. T., Jorcyk C. L., Clinical significance of interleukin (IL)-6 in cancer metastasis to bone:Potential of anti-IL-6 therapies. Cancer Management and Research 2011 3 1 177 189 2-s2.0-79957888198 10.2147/CMR.S18101
176. Samatov T. R., Tonevitsky A. G., Schumacher U., Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Molecular Cancer 2013 12 1, article 107
177. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
178. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. CA Cancer Journal for Clinicians 2013 63 11 30
179. Ooi C. J., Fock K. M., Makharia G. K., Goh K. L., Ling K. L., Hilmi I., Lim W. C., Kelvin T., Gibson P. R., Gearry R. B., Ouyang Q., Sollano J., Manatsathit S., Rerknimitr R., Wei S.-C., Leung W. K., De Silva H. J., Leong R. W., The Asia-Pacific consensus on ulcerative colitis. Journal of Gastroenterology and Hepatology 2010 25 3 453 468 2-s2.0-77649226304 10.1111/j.1440-1746.2010.06241.x
180. Watanabe T., Konishi T., Kishimoto J., Kotake K., Muto T., Sugihara K., Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflammatory Bowel Diseases 2011 17 3 802 808 2-s2.0-79951658625 10.1002/ibd.21365
181. Ullman T. A., Itzkowitz S. H., Intestinal inflammation and cancer. Gastroenterology 2011 140 6 1807 1816 2-s2.0-79955564023 10.1053/j.gastro.2011. 01.057
182. Soetikno R. M., Lin O. S., Heidenreich P. A., Young H. S., Blackstone M. O., Increased risk of colorectal neoplasia in patiets with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointestinal Endoscopy 2002 56 1 48 54 2-s2.0-0036637281 10.1067/mge.2002.125367 (Pubitemid 41115048)
183. Chassaing B., Darfeuillemichaud A., The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011 140 6 1720 1728 2-s2.0-79955554300 10.1053/j.gastro.2011. 01.054
184. de la Fuente M., Franchi L., Araya D., Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. International Journal of Medical Microbiology 2014
185. Sasaki M., Sitaraman S. V., Babbin B. A., Gerner-Smidt P., Ribot E. M., Garrett N., Alpern J. A., Akyildiz A., Theiss A. L., Nusrat A., Klapproth J.-M. A., Invasive Escherichia coli are a feature of Crohn's disease. Laboratory Investigation 2007 87 10 1042 1054 2-s2.0-34548770119 10.1038/labinvest.3700661 (Pubitemid 47429187)
186. Nakase H., Tamaki H., Matsuura M., Chiba T., Okazaki K., Involvement of Mycobacterium avium subspecies paratuberculosis in TNF- α production from macrophage: possible link between MAP and immune response in Crohn's disease. Inflammatory Bowel Diseases 2011 17 11 e140 e142 2-s2.0-80054725762 10.1002/ibd.21750
187. Mizoguchi E., Kanneganti M., Mino-Kenudson M., Animal models of colitis-associated carcinogenesis. Journal of Biomedicine and Biotechnology 2011 2011 23 2-s2.0-79952224171 10.1155/2011/342637 342637
188. Okayasu I., Yamada M., Mikami T., Yoshida T., Kanno J., Ohkusa T., Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. Journal of Gastroenterology and Hepatology 2002 17 10 1078 1083 2-s2.0-0036051423 10.1046/j.1440-1746.2002.02853.x (Pubitemid 35013962)
189. Cooper H. S., Murthy S., Kido K., Yoshitake H., Flanigan A., Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000 21 4 757 768 2-s2.0-0034052970 (Pubitemid 30214034)
190. Tanaka T., Kohno H., Suzuki R., Yamada Y., Sugie S., Mori H., A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Science 2003 94 11 965 973 2-s2.0-0344237231 10.1111/j.1349-7006.2003.tb01386.x (Pubitemid 37508979)
191. Takahashi M., Mutoh M., Kawamori T., Sugimura T., Wakabayashi K., Altered expression of β -catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 2000 21 7 1319 1327 2-s2.0-0033924401 (Pubitemid 30455990)
192. Olsen T., Goll R., Cui G., Husebekk A., Vonen B., Birketvedt G. S., Florholmen J., Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scandinavian Journal of Gastroenterology 2007 42 11 1312 1320 2-s2.0-35148833220 10.1080/ 00365520701409035 (Pubitemid 47537070)
193. Kusugami K., Fukatsu A., Tanimoto M., Shinoda M., Haruta J., Kuroiwa A., Ina K., Kanayama K., Ando T., Matsuura T., Yamaguchi T., Morise K., Ieda M., Iokawa H., Ishihara A., Sarai S., Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Digestive Diseases and Sciences 1995 40 5 949 959 2-s2.0-0029017776
194. Popivanova B. K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N., Blocking TNF- α in mice reduces colorectal carcinogenesis associated with chronic colitis. Journal of Clinical Investigation 2008 118 2 560 570 2-s2.0-38849171267 10.1172/JCI32453 (Pubitemid 351206546)
195. Seril D. N., Liao J., Yang G.-Y., Yang C. S., Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003 24 3 353 362 2-s2.0-0037357426 10.1093/carcin/24.3. 353 (Pubitemid 36432628)
196. Hussain S. P., Amstad P., Raja K., Ambs S., Nagashima M., Bennett W. P., Shields P. G., Ham A.-J., Swenberg J. A., Marrogi A. J., Harris C. C., Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Research 2000 60 13 3333 3337 2-s2.0-0346606862 (Pubitemid 30482141)
197. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., Imai Y., Shimomukai H., Nomura Y., Matsuda Y., Matsuzawa Y., High levels of transforming growth factor in patients with colorectal cancer: association with disease progression. Gastroenterology 1996 110 2 375 382 2-s2.0-0030024536 10.1053/gast.1996.v110.pm8566583 (Pubitemid 26043869)
198. Lawrance I. C., Maxwell L., Doe W., Inflammation location, but not type, determines the increase in TGF- β 1 and IGF-1 expression and collagen deposition in IBD intestine. Inflammatory Bowel Diseases 2001 7 1 16 26
199. Scaldaferri F., Vetrano S., Sans M., Arena V., Straface G., Stigliano E., Repici A., Sturm A., Malesci A., Panes J., Yla-Herttuala S., Fiocchi C., Danese S., VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009 136 2 585 595 2-s2.0-58649111743 10.1053/j.gastro.2008.09.064
200. Waldner M. J., Wirtz S., Jefremow A., Warntjen M., Neufert C., Atreya R., Becker C., Weigmann B., Vieth M., Rose-John S., Neurath M. F., VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Journal of Experimental Medicine 2010 207 13 2855 2868 2-s2.0-78650407055 10.1084/jem.20100438
201. Kikuchi Y., Kashima T. G., Nishiyama T., Shimazu K., Morishita Y., Shimazaki M., Kii I., Horie H., Nagai H., Kudo A., Fukayama M., Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. Journal of Histochemistry and Cytochemistry 2008 56 8 753 764 2-s2.0-47249162068 10.1369/jhc.2008.951061 (Pubitemid 351991088)
202. Bao S., Ouyang G., Bai X., Huang Z., Ma C., Liu M., Shao R., Anderson R. M., Rich J. N., Wang X.-F., Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004 5 4 329 339 2-s2.0-11144357346 10.1016/S1535-6108(04)00081-9 (Pubitemid 38482069)
203. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y., Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003 52 1 65 70 2-s2.0-0037216498 10.1136/gut.52.1.65 (Pubitemid 36020767)
204. Hyun Y. S., Han D. S., Lee A. R., Eun C. S., Youn J., Kim H.-Y., Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012 33 4 931 936 2-s2.0-84859602743 10.1093/carcin/bgs106
205. Farrar M. A., Schreiber R. D., The molecular cell biology of interferon- γ and its receptor. Annual Review of Immunology 1993 11 571 611 2-s2.0-0027411525 (Pubitemid 23115018)
206. Harada A., Sekido N., Akahoshi T., Wada T., Mukaida N., Matsushima K., Essential involvement of interleukin-8 (IL-8) in acute inflammation. Journal of Leukocyte Biology 1994 56 5 559 564 2-s2.0-0027988669 (Pubitemid 24348812)
207. Daig R., Andus T., Aschenbrenner E., Falk W., Schölmerich J., Gross V., Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996 38 2 216 222 2-s2.0-0030067724
208. Mazzucchelli L., Hauser C., Zgraggen K., Wagner H., Hess M., Laissue J. A., Mueller C., Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. American Journal of Pathology 1994 144 5 997 1007 2-s2.0-0028275028 (Pubitemid 24160640)
209. Grimm M. C., Elsbury S. K. O., Pavli P., Doe W. F., Interleukin 8: cells of origin in inflammatory bowel disease. Gut 1996 38 1 90 98 2-s2.0-0030071347 (Pubitemid 26022524)
210. Li A., Varney M. L., Singh R. K., Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clinical Cancer Research 2001 7 10 3298 3304 2-s2.0-0034792393 (Pubitemid 32963857)
211. Cacev T., Radosević S., Krizanac S., Kapitanović S., Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008 29 8 1572 1580
212. Heidemann J., Ogawa H., Dwinell M. B., Rafiee P., Maaser C., Gockel H. R., Otterson M. F., Ota D. M., Lügering N., Domschkell W., Binion D. G., Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. Journal of Biological Chemistry 2003 278 10 8508 8515 2-s2.0-0037424253 10.1074/jbc.M208231200 (Pubitemid 36800603)
213. Everhart J. E., Ruhl C. E., Burden of digestive diseases in the United States-part III: liver, biliary tract, and pancreas. Gastroenterology 2009 136 4 1134 1144 2-s2.0-62949143802 10.1053/j.gastro.2009.02.038
214. Shaib Y., El-Serag H. B., The epidemiology of cholangiocarcinoma. Seminars in Liver Disease 2004 24 2 115 125 2-s2.0-2942615272 10.1055/s-2004-828889 (Pubitemid 38738341)
215. Sripa B., Pairojkul C., Cholangiocarcinoma: lessons from Thailand. Current Opinion in Gastroenterology 2008 24 3 349 356 2-s2.0-42149173756 10.1097/MOG.0b013e3282fbf9b3 (Pubitemid 351535894)
216. Tyson G. L., El-Serag H. B., Risk factors for cholangiocarcinoma. Hepatology 2011 54 1 173 184 2-s2.0-79959572626 10.1002/hep.24351
217. Fevery J., Verslype C., Lai G., Aerts R., van Steenbergen W., Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Digestive Diseases and Sciences 2007 52 11 3123 3135 2-s2.0-34848824769 10.1007/s10620-006-9681-4 (Pubitemid 47512534)
218. Charatcharoenwitthaya P., Enders F. B., Halling K. C., Lindor K. D., Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008 48 4 1106 1117 2-s2.0-54449084021 10.1002/hep.22441
219. Burak K., Angulo P., Pasha T. M., Egan K., Petz J., Lindor K. D., Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. American Journal of Gastroenterology 2004 99 3 523 526 2-s2.0-1942440342 10.1111/j.1572-0241.2004.04067.x (Pubitemid 38524134)
220. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V., A review of human carcinogens-part B: biological agents. The Lancet Oncology 2009 10 4 321 322 2-s2.0-64849105830
221. Sripa B., Bethony J. M., Sithithaworn P., Kaewkes S., Mairiang E., Loukas A., Mulvenna J., Laha T., Hotez P. J., Brindley P. J., Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Tropica 2011 120 1 S158 S168 2-s2.0-79958016674 10.1016/j.actatropica.2010.07.006
222. Min K. L., Ju Y.-H., Franceschi S., Oh J.-K., Kong H.-J., Hwang S.-S., Park S.-K., Cho S.-I., Sohn W.-M., Kim D.-I., Yoo K.-Y., Hong S.-T., Shin H.-R., Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the republic of korea. American Journal of Tropical Medicine and Hygiene 2006 75 1 93 96 2-s2.0-43049123130 (Pubitemid 351627576)
223. Zhou X., Peng W., Crompton D. W. T., Xiong J., Treatment of biliary ascariasis in China. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999 93 6 561 564 2-s2.0-0006690923 (Pubitemid 30015771)
224. Mukhopadhyay M., Biliary ascariasis in the Indian subcontinent: a study of 42 cases. Saudi Journal of Gastroenterology 2009 15 2 121 124 2-s2.0-64149129764 10.4103/1319-3767.48970
225. Di Bisceglie A. M., Hepatitis B and hepatocellular carcinoma. Hepatology 2009 49 5 S56 S60 2-s2.0-66149163340 10.1002/hep.22962
226. Lee T. Y., Lee S. S., Jung S. W., Jeon S. H., Yun S.-C., Oh H.-C., Kwon S., Lee S. K., Seo D. W., Kim M.-H., Suh D. J., Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. American Journal of Gastroenterology 2008 103 7 1716 1720 2-s2.0-50649112820 10.1111/j.1572-0241.2008.01796.x
227. Isa T., Tomita S., Nakachi A., Miyazato H., Shimoji H., Kusano T., Muto Y., Furukawa M., Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology 2002 49 45 604 608 2-s2.0-0036016638 (Pubitemid 34615308)
228. Wang Y., Yamaguchi Y., Watanabe H., Ohtsubo K., Wakabayashi T., Sawabu N., Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K-ras mutation. Journal of Gastroenterology 2002 37 10 831 839 2-s2.0-0036812968 10.1007/s005350200137 (Pubitemid 35390303)
229. Itoi T., Takei K., Shinohara Y., Takeda K., Nakamura K., Horibe T., Sanada A., Ohno H., Matsubayashi H., Saito T., Watanabe H., K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathology International 1999 49 1 30 37 2-s2.0-0032875327 10.1046/j.1440-1827.1999.00821. x (Pubitemid 29421945)
230. Aishima S.-I., Taguchi K.-I., Sugimachi K., Shimada M., Sugimachi K., Tsuneyoshi M., c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002 40 3 269 278 2-s2.0-0036124041 10.1046/j.1365-2559.2002.00353.x (Pubitemid 34227118)
231. Okaro A. C., Deery A. R., Hutchins R. R., Davidson B. R., The expression of antiapoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. Journal of Clinical Pathology 2001 54 12 927 932 2-s2.0-0035675874 (Pubitemid 34032887)
232. Taniai M., Higuchi H., Burgart L. J., Gores G. J., p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002 123 4 1090 1098 2-s2.0-0036771842 10.1053/gast.2002.36021
233. Boonjaraspinyo S., Wu Z., Boonmars T., Kaewkes S., Loilome W., Sithithaworn P., Nagano I., Takahashi Y., Yongvanit P., Bhudhisawasdi V., Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitology International 2012 61 1 145 150 2-s2.0-82655181921 10.1016/j.parint.2011.07.008
234. Boonjaraspinyo S., Boonmars T., Wu Z., Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumor Biology 2012 33 5 1785 1802
235. Drucker D. J., Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002 122 2 531 544 2-s2.0-0036158954 (Pubitemid 34117003)
236. Marzioni M., Alpini G., Saccomanno S., Candelaresi C., Venter J., Rychlicki C., Fava G., Francis H., Trozzi L., Glaser S., Benedetti A., Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007 133 1 244 255 2-s2.0-34447095397 10.1053/j.gastro.2007.04.007 (Pubitemid 47031126)
237. Gaudio E., Barbaro B., Alvaro D., Glaser S., Francis H., Ueno Y., Meininger C. J., Franchitto A., Onori P., Marzioni M., Taffetani S., Fava G., Stoica G., Venter J., Reichenbach R., De Morrow S., Summers R., Alpini G., Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006 130 4 1270 1282 2-s2.0-33646472475 10.1053/j.gastro.2005.12.034
238. Gaudio E., Barbaro B., Alvaro D., Glaser S., Francis H., Franchitto A., Onori P., Ueno Y., Marzioni M., Fava G., Venter J., Reichenbach R., Summers R., Alpini G., Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006 291 2 G307 G317 2-s2.0-33745770227 10.1152/ajpgi.00507.2005 (Pubitemid 44024691)
239. Sirica A. E., Nathanson M. H., Gores G. J., LaRusso N. F., Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference. Hepatology 2008 48 6 2040 2046 2-s2.0-58149401287 10.1002/hep.22623
240. Hanahan D., Coussens L. M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012 21 3 309 322 2-s2.0-84858590826 10.1016/j.ccr.2012.02.022
241. Chuaysri C., Thuwajit P., Paupairoj A., Chau-In S., Suthiphongchai T., Thuwajit C., Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncology Reports 2009 21 4 957 969 2-s2.0-67449098972 10.3892/or-00000309
242. Utispan K., Thuwajit P., Abiko Y., Charngkaew K., Paupairoj A., Chau-in S., Thuwajit C., Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Molecular Cancer 2010 9, article 13 2-s2.0-77649298501 10.1186/1476-4598-9-13
243. Sirica A. E., The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nature Reviews Gastroenterology and Hepatology 2012 9 1 44 54 2-s2.0-84655169986 10.1038/nrgastro.2011.222
244. Rizvi S., Gores G. J., Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013 145 6 1215 1229
245. Sirica A. E., Campbell D. J., Dumur C. I., Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology 2011 27 3 276 284 2-s2.0-79955060818 10.1097/MOG.0b013e32834405c3 Tecnológico Científica y Tecnológica